InvestorsHub Logo
Followers 65
Posts 2029
Boards Moderated 0
Alias Born 10/31/2017

Re: None

Saturday, 06/19/2021 12:40:50 PM

Saturday, June 19, 2021 12:40:50 PM

Post# of 302
haTTR is a rare disease with currently two antisense treatment options from Alnylam (leader) and Ionis (alternative). These launched recently and adoption os as expected for a solid rare disease launch.

They come with their benefits and drawbacks which are now generating about $500M annual revenue with a 12% growth clip as these get adopted worldwide. There remains unmet medical need in this disease and there are advantages to a one and done approach. Solving how to price and recover gene editing value is another question.

https://investors.alnylam.com/press-release?id=25686

https://investor.precisionbiosciences.com/news-releases/news-release-details/new-preclinical-data-presented-2021-american-society-genetic
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DTIL News